Advanced search
Publication Cover
Current Medical Research and Opinion Volume 21, 2005 - Issue 1
Submit an article Journal homepage
52
Views
16
CrossRef citations to date
0
Altmetric
Original Article

Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial

Cheryl A. Keech Eli Lilly and Company, Indianapolis, IN, USA
,
Andreas Sashegyi Eli Lilly and Company, Indianapolis, IN, USA
&
Elizabeth Barrett-Connor University of California, San Diego, CA, USACorrespondence[email protected]
Pages 135-140 | Accepted 24 Nov 2004, Published online: 07 Jan 2005

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Victoria LT Ballard & Jay M Edelberg. (2007) Targets for regulating angiogenesis in the ageing endothelium. Expert Opinion on Therapeutic Targets 11:11, pages 1385-1399.
Read now

Articles from other publishers (15)

Jasna Markovac & Robert Marcus. 2020. Principles of Bone Biology. Principles of Bone Biology 863 893 .
Heidi D. Nelson, Rongwei Fu, Bernadette Zakher, Miranda Pappas & Marian McDonagh. (2019) Medication Use for the Risk Reduction of Primary Breast Cancer in Women. JAMA 322:9, pages 868.
Crossref
Douglas K. Owens, Karina W. Davidson, Alex H. Krist, Michael J. Barry, Michael Cabana, Aaron B. Caughey, Chyke A. Doubeni, John W. EplingJrJr, Martha Kubik, C. Seth Landefeld, Carol M. Mangione, Lori Pbert, Michael Silverstein, Chien-Wen Tseng & John B. Wong. (2019) Medication Use to Reduce Risk of Breast Cancer. JAMA 322:9, pages 857.
Crossref
Mohammad M. Khan. (2016) Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia. CNS Drugs 30:7, pages 589-601.
Crossref
Elizabeth J Samelson, Paul D Miller, Claus Christiansen, Nadia S Daizadeh, Luanda Grazette, Mary S Anthony, Ogo Egbuna, Andrea Wang, Suresh R Siddhanti, Angela M Cheung, Nathalie Franchimont & Douglas P Kiel. (2014) RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk. Journal of Bone and Mineral Research 29:2, pages 450-457.
Crossref
Akihisa Ikeno, Hisao Minato, Chie Kohayakawa & Jun-ichi Tsuji. (2009) Effect of OS-0544, a selective estrogen receptor modulator, on endothelial function and increased sympathetic activity in ovariectomized rats. Vascular Pharmacology 50:1-2, pages 40-44.
Crossref
Wendy Shelly, Michael W. Draper, Venkatesh Krishnan, Mayme Wong & Robert B. Jaffe. (2008) Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings. Obstetrical & Gynecological Survey 63:3, pages 163-181.
Crossref
Henry U. Bryant. 2008. Principles of Bone Biology. Principles of Bone Biology 887 919 .
Wendy J. MackBala DhunganaSherie A. DowsettCheryl A. KeechMei FengYanjie LiHoward N. Hodis. (2007) Carotid Artery Intima-Media Thickness after Raloxifene Treatment. Journal of Women's Health 16:3, pages 370-378.
Crossref
FELICIA COSMAN & ROBERT LINDSAY. 2007. Treatment of the Postmenopausal Woman. Treatment of the Postmenopausal Woman 837 845 .
Chiara BolegoElisabetta VegetoChristian PinnaAdriana MaggiAndrea Cignarella. (2006) Selective Agonists of Estrogen Receptor Isoforms. Arteriosclerosis, Thrombosis, and Vascular Biology 26:10, pages 2192-2199.
Crossref
Christian Alexandre. (2006) Les SERM(s). Revue du Rhumatisme 73:8, pages 828-833.
Crossref
Shanhong Ling, Paul Komesaroff & Krishnankutty Sudhir. (2006) Cellular mechanisms underlying the cardiovascular actions of oestrogens. Clinical Science 111:2, pages 107-118.
Crossref
Chad L DealMichael W Draper. (2016) Raloxifene: A Selective Estrogen-Receptor Modulator for Postmenopausal Osteoporosis – a Clinical Update on Efficacy and Safety. Women's Health 2:2, pages 199-210.
Crossref
Victoria L. BallardJay M. Edelberg. (2005) Harnessing Hormonal Signaling for Cardioprotection. Science of Aging Knowledge Environment 2005:51.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.